Revance Therapeutics Inc. (NASDAQ:RVNC) Director Phyllis Gardner sold 5,333 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $31.51, for a total transaction of $168,042.83. Following the completion of the transaction, the director now directly owns 5,250 shares of the company’s stock, valued at $165,427.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
RVNC stock opened at $30.35 on Monday. Revance Therapeutics Inc. has a 52 week low of $18.42 and a 52 week high of $37.45. The firm has a market cap of $1,114.85, a P/E ratio of -7.57 and a beta of 1.33.
Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. During the same period in the prior year, the business posted ($0.95) EPS. Revance Therapeutics’s revenue for the quarter was down 50.7% on a year-over-year basis. research analysts forecast that Revance Therapeutics Inc. will post -3.56 earnings per share for the current year.
RVNC has been the topic of several recent analyst reports. BidaskClub cut shares of Revance Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 7th. Mizuho restated a “buy” rating and set a $54.00 price objective on shares of Revance Therapeutics in a research report on Friday, January 5th. Cowen set a $55.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 17th. Guggenheim cut shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Barclays set a $40.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. Revance Therapeutics has an average rating of “Buy” and an average price target of $45.17.
Several hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC bought a new position in shares of Revance Therapeutics during the 4th quarter valued at $392,000. Cowen Inc. bought a new position in shares of Revance Therapeutics during the 4th quarter valued at $225,000. Jane Street Group LLC bought a new position in shares of Revance Therapeutics during the 4th quarter valued at $685,000. 1492 Capital Management LLC bought a new position in shares of Revance Therapeutics during the 4th quarter valued at $1,393,000. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of Revance Therapeutics by 4.6% during the 4th quarter. TIAA CREF Investment Management LLC now owns 62,863 shares of the biopharmaceutical company’s stock valued at $2,247,000 after purchasing an additional 2,759 shares during the last quarter. 95.14% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Revance Therapeutics Inc. (NASDAQ:RVNC) Director Phyllis Gardner Sells 5,333 Shares” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/09/revance-therapeutics-inc-rvnc-director-phyllis-gardner-sells-5333-shares.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.